Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug

French drugmaker Sanofi (SNYNF) has received regulatory approval in China for its Dupixent drug, which it is developing together with Regeneron Pharmaceuticals, Inc (REGN).

The two drugmakers said that China’s National Medical Products Administration (NMPA) has approved Dupixent for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.